Research programme: platelet aggregation inhibitors - Evolva Biotech
Latest Information Update: 22 Feb 2010
At a glance
- Originator Evolva Biotech
- Developer Evolva Holding SA
- Mechanism of Action Platelet aggregation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Diabetes mellitus; Inflammation
Most Recent Events
- 14 Dec 2009 Evolva SA has merged with Arpida to form Evolva Holding SA